GHK-Cu — the copper complex of the tripeptide glycyl-L-histidyl-L-lysine — is a naturally occurring molecule found in human plasma, saliva, and urine. First characterized in 1973 by biochemist Loren Pickart, it has accumulated a substantial pre-clinical research record spanning collagen synthesis, wound repair, antioxidant activity, and broad gene-expression modulation. Because of this research profile, injectable formulations have drawn significant interest from the peptide research community.
This article is for educational and research purposes only. Injectable GHK-Cu is not FDA-approved for therapeutic use in humans. Consult a licensed medical professional before considering any peptide protocol.
What Is GHK-Cu?
GHK is a tripeptide (Gly-His-Lys) that binds copper(II) ions with high affinity, forming the GHK-Cu complex. In healthy adults, plasma GHK concentrations have been reported at approximately 200 ng/mL in the third decade of life, declining to roughly 80 ng/mL by the seventh decade — a reduction discussed in the context of age-related changes in tissue remodeling capacity (Pickart & Margolina, Int J Mol Sci, 2018).
Unlike fully synthetic research peptides, GHK-Cu is endogenous — the body produces and uses it physiologically. That fact does not imply exogenous injection is safe or effective at experimental doses; it does provide a starting rationale for the research interest.
What Peer-Reviewed Research Shows
The evidence base is predominantly in vitro and animal-model research. A limited number of human studies exist, primarily for topical application in wound care contexts. Clinicians and researchers should weight the evidence accordingly.
Collagen Synthesis and Wound Healing
In vitro studies documented that GHK-Cu stimulates collagen synthesis in human fibroblast cultures and promotes wound contraction in animal models. Pickart (2008, J Biomater Sci Polym Ed; PMID 18644225) reviewed the tripeptide's role in tissue remodeling, noting enhanced glycosaminoglycan and collagen production at nanomolar concentrations in cell culture. Extrapolation to in vivo human outcomes requires caution: dose-response relationships and systemic pharmacokinetics following injection in humans remain poorly characterized.
Randomized controlled trials on topical copper-peptide wound dressings have shown some acceleration of healing endpoints, but most had sample sizes below 50 participants and heterogeneous product compositions, making attribution to GHK-Cu alone unreliable.
Gene Expression Modulation
The 2018 review by Pickart & Margolina (Int J Mol Sci, 19(7):1987; DOI 10.3390/ijms19071987; PMID 29986520) analyzed publicly available gene-expression databases and identified associations between GHK-Cu exposure and modulation of pathways linked to inflammation, DNA repair, and antioxidant defense — reportedly spanning thousands of human genes. This analysis was computational and database-derived. It generates hypotheses; it does not confirm clinical outcomes in humans.
Antioxidant and Anti-Inflammatory Activity
GHK-Cu has been shown in cell-culture models to induce superoxide dismutase (SOD) expression and suppress pro-inflammatory cytokines (TNF-α, IL-6) under experimental conditions. Whether equivalent effects occur in vivo at plasma concentrations achievable by subcutaneous injection in humans is not established by current clinical evidence.
Injectable vs. Topical GHK-Cu — Key Differences
| Form | Typical Use | Evidence Level | Regulatory Status |
|---|---|---|---|
| Topical (cream/serum) | Cosmetic skin care, wound dressings | Some human data for skin outcomes | Cosmetic ingredient — no drug approval required for cosmetic claims |
| Injectable (subcutaneous) | Peptide research protocols | Pre-clinical (in vitro, animal); minimal human data | Not FDA-approved as a drug; sold as RUO in the US |
The bioavailability difference is substantial. Topical GHK-Cu is subject to dermal absorption limitations; injectable forms bypass this barrier entirely, delivering the peptide systemically. This increases both potential systemic effect and potential risk — a distinction researchers must account for in protocol design.
Regulatory Status
United States (FDA): GHK-Cu has no FDA-approved new drug application (NDA) for any indication. Injectable formulations marketed to humans as therapeutic agents would be classified as unapproved drugs. In the research context, GHK-Cu is legally sold under a Research Use Only (RUO) designation, explicitly not intended for human use.
April 2026 compounding update: In April 2026, FDA removed GHK-Cu injectable from the Category 2 bulk drug substances list — the category reserved for substances flagged as presenting significant safety concerns. This removal does not constitute therapeutic approval; it moves GHK-Cu injectable to pending formal evaluation by the Pharmacy Compounding Advisory Committee (PCAC), with a hearing scheduled for February 2027. Compounding pharmacies and prescribers should consult the FDA's current 503A/503B bulk drug substance lists for updated guidance before compounding GHK-Cu injectables.
Brazil (ANVISA): GHK-Cu is not listed among ANVISA controlled substances. Compounded injectable peptides for clinical use fall under the magistral formulation framework, historically anchored in RDC 204/2017 but subject to subsequent resolutions including regulatory updates issued in 2024 and 2025 (RDC 843/2024; RDC 948/2024; RDC 1004/2025). The regulatory landscape for injectable compounded peptides in Brazil is actively evolving; regional medical councils (including CRM-PR) have issued technical alerts regarding invasive peptide use. A licensed physician's prescription is required for any injectable compounded formulation dispensed to a patient; prescribers should verify current ANVISA guidance before initiating any compounded injectable peptide protocol.
WADA: As of the 2026 Prohibited List, GHK-Cu is not explicitly named as a prohibited substance. Athletes subject to anti-doping testing should verify the current list directly at wada-ama.org or with their national anti-doping authority, as peptide regulations are updated annually.
Where Injectable GHK-Cu Is Sourced for Research
The query "where to buy GHK-Cu injection" reflects two distinct legitimate sourcing pathways — and one that researchers should actively avoid.
1. Peptide Research Suppliers (RUO)
Chemical research companies sell lyophilized GHK-Cu powder in research-grade vials (commonly 50–200 mg per vial), explicitly labeled For Research Use Only — Not For Human Use. These suppliers serve academic laboratories, pre-clinical research teams, and the broader longevity-research community.
Quality markers to require before any purchase:
- Certificate of Analysis (CoA) from an independent third-party laboratory
- HPLC purity report — the accepted research benchmark is ≥98% purity
- Mass spectrometry confirmation of molecular identity (GHK free peptide: ~340 Da; GHK-Cu complex: ~403 Da)
- Sterility and endotoxin data if the product will be reconstituted for in vivo animal research
A reputable RUO supplier will not market GHK-Cu with therapeutic claims or suggest human supplementation on packaging or product pages. Such language is a regulatory red flag and a signal of low-quality sourcing practices.
2. Compounding Pharmacies (Prescription)
In the United States and Brazil, some physicians prescribe compounded GHK-Cu injectable formulations through licensed compounding pharmacies — produced under USP 797 sterile-compounding standards (US) or the current ANVISA magistral formulation framework (Brazil). This is the only pathway that produces a pharmaceutically manufactured injectable dispensed legitimately under physician supervision for a named patient.
Availability varies by jurisdiction and evolves with regulatory guidance. In the US, the April 2026 FDA compounding list update makes the access landscape more favorable than in prior years, though formal PCAC evaluation is pending. Physicians should consult current state or national pharmacy board guidance before prescribing compounded peptides.
What to Avoid
- Products marketed directly as injectable supplements without an RUO designation
- Suppliers who cannot produce a verifiable, third-party CoA on request
- Pre-mixed liquid GHK-Cu solutions without documented sterility and endotoxin testing
Related Peptides in Longevity and Tissue Research
Researchers studying GHK-Cu often investigate it alongside peptides with complementary mechanistic profiles:
- Epithalon — a tetrapeptide studied for telomerase activation and epigenetic regulation; like GHK-Cu, characterized primarily by pre-clinical and observational data.
- Thymosin Alpha-1 — a thymic peptide with extensive human clinical data in immune-modulation contexts; one of the better-characterized injectable peptides in terms of human trial evidence.
- BPC-157 — a synthetic pentadecapeptide with an extensive animal-model record for tissue repair and cytoprotection, frequently co-researched with GHK-Cu in regenerative protocols. Athletes note: BPC-157 is prohibited by WADA under both S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances) — it is banned at all times, including during training.
Consult a Qualified Professional
GHK-Cu research is scientifically interesting, but translation from cell culture and animal models to human therapeutic use has not been established through controlled clinical trials. Any individual considering injectable peptide protocols should do so only under the supervision of a licensed healthcare provider familiar with the current regulatory and safety landscape.